NAMS

NewAmsterdam Pharma Company
NAMS

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$2.05B
EV
$1.24B
Shares Outstanding
119.55M
Beta
0.01

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$42.44
P/E 2025E
-
P/Revenue 2025E
103.44x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About NewAmsterdam Pharma Company N.V.

gainify
NAMS

NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in v...

Sector

Healthcare

Industry

Biotechnology

CEO

Davidson, Michael

Employees

77

IPO Date

2021-02-09

Headquarters

Gooimeer 2-35, Naarden, Noord-Holland, 1411 DC, Netherlands

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on Threads
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.